Forte Biosciences (FBRX) Competitors $6.88 -0.28 (-3.91%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. GNFT, INMB, ESPR, INBX, ACTU, DERM, IPHA, HURA, TVGN, and ACIUShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Genfit (GNFT), INmune Bio (INMB), Esperion Therapeutics (ESPR), Inhibrx (INBX), Actuate Therapeutics (ACTU), Journey Medical (DERM), Innate Pharma (IPHA), TuHURA Biosciences (HURA), Tevogen Bio (TVGN), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Genfit INmune Bio Esperion Therapeutics Inhibrx Actuate Therapeutics Journey Medical Innate Pharma TuHURA Biosciences Tevogen Bio AC Immune Forte Biosciences (NASDAQ:FBRX) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations. Is FBRX or GNFT more profitable? Genfit's return on equity of 0.00% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -151.43% -118.92% Genfit N/A N/A N/A Which has more risk & volatility, FBRX or GNFT? Forte Biosciences has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Do analysts prefer FBRX or GNFT? Forte Biosciences currently has a consensus price target of $32.50, indicating a potential upside of 372.38%. Genfit has a consensus price target of $13.00, indicating a potential upside of 208.06%. Given Forte Biosciences' higher probable upside, equities research analysts clearly believe Forte Biosciences is more favorable than Genfit.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in FBRX or GNFT? Genfit received 38 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 69.70% of users gave Genfit an outperform vote while only 62.00% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformForte BiosciencesOutperform Votes3162.00% Underperform Votes1938.00% GenfitOutperform Votes6969.70% Underperform Votes3030.30% Do insiders & institutionals believe in FBRX or GNFT? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 3.1% of Forte Biosciences shares are held by insiders. Comparatively, 4.2% of Genfit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, FBRX or GNFT? Genfit has higher revenue and earnings than Forte Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$31.48M-$16.29-0.42Genfit$76.06M2.77-$31.27MN/AN/A Does the media refer more to FBRX or GNFT? In the previous week, Genfit had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 4 mentions for Genfit and 2 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.25 beat Genfit's score of 0.17 indicating that Forte Biosciences is being referred to more favorably in the media. Company Overall Sentiment Forte Biosciences Positive Genfit Neutral SummaryGenfit beats Forte Biosciences on 8 of the 13 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.28M$6.84B$5.55B$8.05BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-0.427.4722.7318.81Price / SalesN/A262.04406.97107.57Price / CashN/A65.8538.1834.62Price / Book0.286.636.814.34Net Income-$31.48M$143.37M$3.22B$247.85M7 Day Performance2.53%4.01%2.40%2.83%1 Month Performance-6.39%6.44%3.77%3.46%1 Year PerformanceN/A-2.08%16.96%5.87% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences3.5125 of 5 stars$6.88-3.9%$32.50+372.4%+26,576.6%$45.28MN/A-0.425Options VolumePositive NewsGap UpGNFTGenfit1.361 of 5 stars$3.67+0.8%$13.00+254.2%+20.0%$183.49M$76.06M0.00120Short Interest ↑Gap UpINMBINmune Bio2.3585 of 5 stars$7.90+1.0%$22.80+188.6%-34.6%$181.57M$14,000.00-3.6210Upcoming EarningsNews CoveragePositive NewsESPREsperion Therapeutics3.4788 of 5 stars$0.91-1.4%$6.42+607.2%-51.8%$179.78M$332.31M-1.42200Upcoming EarningsAnalyst RevisionNews CoverageGap UpINBXInhibrx2.3457 of 5 stars$12.35+0.7%N/A-64.1%$178.78M$200,000.000.00166Short Interest ↓News CoveragePositive NewsACTUActuate TherapeuticsN/A$9.05+1.1%$20.50+126.5%N/A$176.77MN/A0.0010DERMJourney Medical2.6698 of 5 stars$7.58+1.5%$9.88+30.3%+96.0%$175.13M$56.13M-8.0690Short Interest ↑News CoverageIPHAInnate Pharma2.5786 of 5 stars$2.09+5.5%$11.00+426.6%-11.7%$175.12M$12.63M0.00220HURATuHURA BiosciencesN/A$3.97-3.2%$12.67+219.1%N/A$173.41MN/A0.00N/APositive NewsTVGNTevogen Bio3.0931 of 5 stars$0.94-5.5%$7.10+657.4%+0.9%$172.38MN/A0.003Analyst ForecastACIUAC Immune2.2785 of 5 stars$1.70+3.7%$12.00+605.9%-33.2%$170.70M$27.31M-3.70140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies GNFT Competitors INMB Competitors ESPR Competitors INBX Competitors ACTU Competitors DERM Competitors IPHA Competitors HURA Competitors TVGN Competitors ACIU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
